# Study of the Safety and Efficacy of Long-Term Rilonacept Treatment for the Prevention of Gout Flares

> **NCT01459796** · PHASE3 · TERMINATED · sponsor: **Regeneron Pharmaceuticals** · enrollment: 220 (actual)

## Conditions studied

- Gout

## Interventions

- **DRUG:** Rilonacept
- **DRUG:** Placebo
- **DRUG:** Allopurinol

## Key facts

- **NCT ID:** NCT01459796
- **Lead sponsor:** Regeneron Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2011-11
- **Primary completion:** 2013-06
- **Final completion:** 2013-06
- **Target enrollment:** 220 (ACTUAL)
- **Last updated:** 2017-07-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01459796

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01459796, "Study of the Safety and Efficacy of Long-Term Rilonacept Treatment for the Prevention of Gout Flares". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01459796. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*